|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.42 USD | +1.87% |
|
+0.06% | +30.41% |
| 22/07 | Celldex Therapeutics, Inc. - Special Call | |
| 22/07 | Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says | MT |
| Market Cap | 278.02Cr 244.52Cr 227.16Cr 208.92Cr 391.8Cr 27TCr 398.82Cr 2.72TCr 1.06TCr 13TCr 1.04TCr 1.02TCr 46TCr | P/E 2026 * |
-8.16x | P/E 2027 * | -8.16x |
|---|---|---|---|---|---|
| Enterprise Value | 219.61Cr 193.14Cr 179.43Cr 165.03Cr 309.48Cr 21TCr 315.03Cr 2.15TCr 836.9Cr 10TCr 824.45Cr 806.62Cr 36TCr | EV / Sales 2026 * |
909x | EV / Sales 2027 * | 205x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +1.87% | ||
| 1 week | +0.06% | ||
| Current month | -4.81% | ||
| 1 month | +7.40% | ||
| 3 months | +5.57% | ||
| 6 months | +36.65% | ||
| Current year | +30.41% |
| 1 week | 33.37 |  | 36.65 |
| 1 month | 33.37 | | 40.3 |
| Current year | 22.33 | | 40.3 |
| 1 year | 19.72 | | 40.3 |
| 3 years | 14.4 | | 53.18 |
| 5 years | 14.4 | | 57.2 |
| 10 years | 1.5 | | 75.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/06/26 | Free | General Counsel | 93,000 | 0.1185% | ||
| 25/06/26 | Free | Chief Administrative Officer | 95,000 | 0.1210% | ||
| 25/06/26 | Free | Director | 26,000 | 0.0331% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.87% | +0.06% | +48.39% | -2.72% | 278.02Cr | |
| +1.57% | -3.17% | -2.93% | +13.24% | 4.63TCr | |
| +3.13% | +5.34% | +402.93% | +605.08% | 4.01TCr | |
| +2.14% | +2.95% | +10.83% | +65.45% | 3.63TCr | |
| +4.43% | -1.51% | +6.73% | -9.17% | 3.46TCr | |
| +1.23% | -2.05% | +0.56% | +30.76% | 2.68TCr | |
| +0.29% | -2.75% | - | - | 1.67TCr | |
| +14.71% | +12.62% | +38.50% | +146.99% | 1.69TCr | |
| +0.67% | -5.29% | +1.00% | +8.76% | 1.31TCr | |
| +1.82% | +0.19% | +1.45% | -30.74% | 1.3TCr | |
| Average | +3.19% | +0.42% | +56.39% | +91.96% | 2.47TCr | |
| Weighted average by Cap. | +3.06% | +0.22% | +76.06% | +130.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.16L 21.25L 19.74L 18.16L 34.05L 23Cr 34.66L 2.36Cr 92.09L 11Cr 90.72L 88.76L 40Cr | 1.1Cr 97.12L 90.22L 82.98L 1.56Cr 106.94Cr 1.58Cr 11Cr 4.21Cr 52Cr 4.15Cr 4.06Cr 180.95Cr |
| Net income | -33Cr -29Cr -27Cr -25Cr -47Cr -3.2TCr -47Cr -322.48Cr -125.78Cr -1.56TCr -123.91Cr -121.23Cr -5.41TCr | -37Cr -32Cr -30Cr -28Cr -52Cr -3.56TCr -53Cr -359.05Cr -140.05Cr -1.74TCr -137.96Cr -134.98Cr -6.02TCr |
| Net Debt | -58Cr -51Cr -48Cr -44Cr -82Cr -5.66TCr -84Cr -570.69Cr -222.6Cr -2.76TCr -219.29Cr -214.54Cr -9.57TCr | -52Cr -45Cr -42Cr -39Cr -73Cr -4.99TCr -74Cr -503.24Cr -196.29Cr -2.43TCr -193.37Cr -189.19Cr -8.44TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | $35.42 | +1.87% | 8,56,468 |
| 22/26/22 | $34.77 | -2.50% | 19,28,820 |
| 21/26/21 | $35.66 | +0.68% | 13,92,017 |
| 20/26/20 | $35.42 | +0.20% | 5,27,637 |
| 17/26/17 | $35.35 | -0.14% | 11,49,060 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CLDX Stock
Select your edition
All financial news and data tailored to specific country editions
